This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Wolverine Stack (BPC-157 + TB-500)
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict OPTIONAL-ADD MEDIUM-HIGH
For peripheral nerve compression (cubital tunnel-type) context, the Wolverine Stack is the single most mechanism-aligned non-surgical intervention available — peripheral nerve regeneration is BPC-157's strongest preclinical data set (sciatic crush/transection/spinal cord rat models), and TB-500 supplies the cell-migration arm that BPC-157 alone doesn't fully cover. Verdict is OPTIONAL-ADD (not STRONG-CANDIDATE) because (a) it's a targeted recovery intervention, not a daily stack member, (b) a user in this archetype should run behavioral protocol (night splint, ergonomic pad, sleep position) for 2-4 weeks first since 50%+ of mild cubital tunnel resolves without peptides, (c) the cubital-tunnel-cycle protocol already exists as the archetype-specific implementation. Confidence is MEDIUM-HIGH because both component evidence bases are individually solid (BPC-157 = >180 Sikiric papers + 2025 Vasireddi systematic review of 36 articles; TB-500 = robust rodent + equine data + RegeneRx human ophthalmic/cardiac trials on full TB-4); the *combination* is supported by one published human study (Lee & Padgett 2021, n=16 knee pain, 87.5% improvement combined or BPC-only) and overwhelming biohacker community consensus. Would upgrade to STRONG-CANDIDATE post-positive this user N=1 trial. Would downgrade to WATCH-LIST if independent confirmation of BPC-157 effects fails to materialize OR if cancer-promotion signal emerges in any human cohort.
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
Direct relevance | — | a user in this archetype has documented bilateral elbow pain with pressure-based, nerve-feeling presentation on soft surfaces — symptoms consistent with cubital tunnel syndrome (ulnar nerve compression at the medial epicondyle). The Wolverine Stack maps onto this exactly because: 1. BPC-157's strongest preclinical data set is peripheral nerve regeneration — sciatic-nerve crush, transection, and spinal cord rat models all show faster axonal regeneration, increased fiber density, better EMG recovery, and faster functional recovery. Cubital tunnel is the same lesion class (chronic compression → demyelination + Schwann-cell dysfunction at the compression site) — BPC-157's repair signal targets exactly those cells. 2. TB-500's systemic cell-mobilization adds the migrating progenitor cells that BPC-157's local angiogenesis signal needs to populate the regenerating tissue. 3. The pairing is synergistic, not redundant — different mechanism layers (BPC-157 = perfusion + cell-protective + local; TB-500 = motility + actin remodeling + systemic). Implementation: nerve compression peripheral nerve compression cycle is documented separately in /research/stacks/cubital-tunnel-cycle.md — it's the Wolverine Stack with explicit behavioral protocol overlay (night splint at 30-45° flexion, soft elbow pad, ergonomic modifications, sleep position retraining) and weekly clinical assessment (Tinel's sign, elbow flexion test, Froment's sign, Wartenberg's sign). Diagnostic confirmation must precede the cycle: Tinel's sign positive at cubital tunnel, elbow flexion test reproducing symptoms in <60 sec, optional EMG/NCS for severity grading. If diagnostic atypical → see hand surgeon for differential (medial epicondylitis, brachial plexus, C8/T1 radiculopathy) before committing to peptides. Timing recommendation: Run behavioral protocol alone (splint + ergonomic + sleep position) for 2-4 weeks first. If symptoms resolve → no peptides needed (50%+ of mild cubital tunnel resolves with behavioral alone). If symptoms persist or progress → start Wolverine Stack 4-6 week cycle with behavioral protocol continued. |
- Direct relevance—
a user in this archetype has documented bilateral elbow pain with pressure-based, nerve-feeling presentation on soft surfaces — symptoms consistent with cubital tunnel syndrome (ulnar nerve compression at the medial epicondyle). The Wolverine Stack maps onto this exactly because: 1. BPC-157's strongest preclinical data set is peripheral nerve regeneration — sciatic-nerve crush, transection, and spinal cord rat models all show faster axonal regeneration, increased fiber density, better EMG recovery, and faster functional recovery. Cubital tunnel is the same lesion class (chronic compression → demyelination + Schwann-cell dysfunction at the compression site) — BPC-157's repair signal targets exactly those cells. 2. TB-500's systemic cell-mobilization adds the migrating progenitor cells that BPC-157's local angiogenesis signal needs to populate the regenerating tissue. 3. The pairing is synergistic, not redundant — different mechanism layers (BPC-157 = perfusion + cell-protective + local; TB-500 = motility + actin remodeling + systemic). Implementation: nerve compression peripheral nerve compression cycle is documented separately in /research/stacks/cubital-tunnel-cycle.md — it's the Wolverine Stack with explicit behavioral protocol overlay (night splint at 30-45° flexion, soft elbow pad, ergonomic modifications, sleep position retraining) and weekly clinical assessment (Tinel's sign, elbow flexion test, Froment's sign, Wartenberg's sign). Diagnostic confirmation must precede the cycle: Tinel's sign positive at cubital tunnel, elbow flexion test reproducing symptoms in <60 sec, optional EMG/NCS for severity grading. If diagnostic atypical → see hand surgeon for differential (medial epicondylitis, brachial plexus, C8/T1 radiculopathy) before committing to peptides. Timing recommendation: Run behavioral protocol alone (splint + ergonomic + sleep position) for 2-4 weeks first. If symptoms resolve → no peptides needed (50%+ of mild cubital tunnel resolves with behavioral alone). If symptoms persist or progress → start Wolverine Stack 4-6 week cycle with behavioral protocol continued.
▸ Subjective experience (deep)
Onset: No acute "feel" from either peptide individually or combined — these are not psychoactive. Subjective improvements (pain reduction, range of motion, healing rate) emerge gradually over 1-4 weeks. Some users report mild injection-site warmth or transient localized pain immediately post-injection (BPC-157 SC near injury site).
Peak effect: Weeks 3-6 of cycle for most healing applications. Peripheral nerve issues may show longer onset (weeks 4-8) given regeneration timeline.
Common reported improvements (pep-pedia community survey, n=475 responses):
- Recovery/Healing as primary goal: 93%
- "Very effective" rating: 29% (with 37% "too early to tell" — reflects population still on cycle)
- "No side effects": 68%
- "Definitely yes" would recommend: 50%; "Probably yes": 18%
Variability: Outcome highly dependent on (a) injury severity and chronicity, (b) sourcing quality of the peptides, (c) behavioral co-management (e.g., for compression neuropathies, splinting matters more than peptides alone), (d) dosing consistency, (e) adequate cycle length.
▸ Tolerance + cycling deep dive
- Tolerance: No documented tolerance buildup at therapeutic doses
- Recommended cycling: 4-8 week cycle, then minimum 4-week washout. 2-3 cycles per year if outcomes warrant. Not recommended for continuous year-round use (insufficient long-term safety data; theoretical angiogenesis concern over chronic exposure).
- Reset: Standard 4-week minimum washout; 8-12 weeks between cycles preferable
▸ Stacking deep dive
Compatible / synergistic add-ons
- Growth Hormone (HGH) or GH secretagogues (CJC-1295/Ipamorelin) — BPC-157 upregulates GH receptors; combined use may accelerate tissue repair (per pep-pedia interactions data)
- PEG-MGF — activates satellite cells while BPC/TB promote tissue repair through different pathways; may enhance muscle recovery
- GHK-Cu — collagen synthesis + wound healing; no negative interactions; converts Wolverine → GLOW
- Collagen peptides 10-20 g/d — substrate for tendon/ligament repair (already in V4 base)
- NAC 1200 mg, curcumin 500 mg, magnesium glycinate 400 mg, DHA 2 g — all in V4 base; all anti-inflammatory + healing-compatible
- Vitamin D3 5000 IU + K2 100 mcg — bone/connective tissue support
- Cerebrolysin (different mechanism layers; CNS regeneration)
Monitor combination (use with care)
- NSAIDs — BPC-157 has shown protective effects against NSAID-induced GI damage in studies, but long-term combination effects unknown
- Anticoagulants — both peptides promote angiogenesis; monitor for any bleeding issues when combined with blood thinners
Use caution / avoid
- High-dose corticosteroids — anti-trophic conflict; steroids may counteract healing effects
- Active chemotherapy / cancer history — angiogenesis promotion could theoretically support tumor growth (CONTRAINDICATED)
- Ketamine within 24 hr of TB-500 dose — theoretical NMDA-trophic conflict (same flag as Cerebrolysin, low-evidence)
▸ Drug interactions deep dive
- CYP enzymes: Neither BPC-157 nor TB-500 has documented significant CYP induction/inhibition (peptides metabolized by peptidases, not CYPs)
- Contraceptives: No documented interaction
- Other peptides: See "Synergistic stacking" section above
▸ Pharmacogenomics
- No documented pharmacogenomic data specific to either peptide
- General injection-route peptides bypass first-pass metabolism — limited PGx relevance compared to oral drugs
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Gray-market research peptides | Limitless Life | $40-80/10 mg BPC-157; $80-150/5-10 mg TB-500 | High (within gray market) | COA published per batch |
| Gray-market research peptides | Peptide Sciences | Same range | High | Long track record |
| Gray-market research peptides | Cosmic Peptides | Same range | High | Newer but reputable |
| Compounding pharmacy | (Effectively unavailable since FDA Cat 2 listings) | N/A | N/A | Was available pre-2024 with prescription |
| Bulk research chemical | Various unverified vendors | $20-50 | LOW | Avoid — counterfeit / contamination risk |
Cycle cost (Wolverine Stack only, 4-6 weeks): ~$120-230 component cost Cycle cost (with full ancillaries — bac water, syringes, alcohol prep): ~$200-350
Sourcing quality red flags:
- No published HPLC + mass-spec COA per batch
- Prices significantly below market range
- Vials labeled "Thymosin Beta-4" without mass-spec confirmation (full TB-4 = ~5 kDa; TB-500 heptapeptide = ~889 Da — order of magnitude different molecule)
- Vendors without established reputation
▸ Biomarkers to track (deep)
Baseline (before starting)
- Subjective pain rating (1-10) for target injury
- Functional metrics specific to injury (range of motion, grip strength, pinch strength, walking distance, etc.)
- For cubital tunnel specifically: Tinel's sign at medial epicondyle (+/-), elbow flexion test (sec to symptom reproduction), Froment's sign, Wartenberg's sign, 2-point discrimination at ring + small finger
- Photo log if visible injury (skin/wound)
- hsCRP, IL-6, ESR (systemic inflammation baseline)
- CBC + CMP (general safety baseline)
- AST/ALT (hepatic baseline for longer cycles)
- Tumor markers PRN by family history (CA 19-9, AFP, PSA only if clinically indicated — angiogenesis concern flag)
During cycle (weekly)
- Daily subjective pain rating (morning + evening)
- Injection-site observation
- Weekly: functional metrics (Tinel's sign, flexion test, grip dynamometer for cubital tunnel)
- Mid-cycle (week 4): hsCRP repeat to assess systemic anti-inflammatory effect
- Sleep quality (especially for ulnar nerve cases — night-time symptoms)
Post-cycle (4 weeks after stop)
- Repeat all baseline metrics
- Decision on next cycle, behavioral-only maintenance, or escalation
- Optional: repeat EMG/NCS if baseline showed measurable conduction slowing
▸ Controversies / open debates Live debate
- Independent replication of BPC-157 effects: >80% of evidence base is from a single Croatian lab (Sikiric/Seiwerth, Zagreb). Open 2024-2025 academic dispute about confirmation bias and lack of independent replication. The 2025 Vasireddi systematic review (HSS Journal, n=36 articles, 35 preclinical + 1 clinical) is the most comprehensive independent assessment so far.
- TB-500 vs full TB-4: Vendors and clinics conflate the heptapeptide (TB-500, Ac-LKKTETQ, ~889 Da) with the full 43-AA protein (TB-4, ~5 kDa). All RegeneRx human clinical data is on full TB-4, not the LKKTETQ heptapeptide — extrapolating onto injected TB-500 vials is one inferential layer beyond trial evidence.
- TB-500 active metabolite: March 2024 paper reported TB-500 (Ac-LKKTETQ) itself did NOT enhance wound healing in their assay, but its metabolite Ac-LKKTE (5-AA breakdown product) did. Raises possibility that subQ TB-500 only works to the extent it gets cleaved to Ac-LKKTE in vivo.
- FDA 2024 Category 2 listings: Both peptides flagged with "potential safety concerns" without specifics — opens regulatory uncertainty. RFK Jr. announced TB-500 reclassification to Category 1 in Feb 2026 (Joe Rogan Ep. 2461), not yet formally FDA-published as of 2026-05-05.
- Cancer-angiogenesis signal: Theoretical concern (TB-4 overexpressed in multiple cancers; both peptides drive angiogenesis) — causation unresolved but flags non-zero risk for users with cancer history.
- WADA S0 status: Banned at all times — irrelevant for non-tested users like the user in casual MMA, but disqualifying for any sanctioned competition.
- The "Wolverine Stack" name itself: Marketing — capitalizes on Marvel character regenerative ability. No clinical literature uses this label. Pep-pedia and biohacker community use only.
- Lee & Padgett 2021 study: Only published human study combining BPC-157 + TB-4. Small (n=16), retrospective, knee pain only, intra-articular injection (not SC). 87.5% improvement reported but n=4 in combination arm = 3/4 improvement (75%); BPC-157 alone n=12 = 11/12 (91.6%). Suggests BPC-157 alone may be sufficient for many indications; TB-500 add-on benefit is less clear in published human data.
▸ Verdict change log
- 2026-05-06 — Initial verdict: OPTIONAL-ADD with MEDIUM-HIGH confidence. Targeted recovery intervention specifically applicable to nerve compression peripheral nerve compression context (already detailed in
cubital-tunnel-cycle.md). Not a daily/maintenance stack member. Confidence MEDIUM-HIGH because component evidence is individually strong (BPC-157 = >180 papers + 2025 Vasireddi systematic review; TB-500 = robust rodent/equine + RegeneRx human ophthalmic/cardiac on full TB-4); combination synergy supported by mechanism + Lee & Padgett 2021 (n=16) + biohacker community consensus.
▸ Open questions / gaps Open
- Independent (non-Sikiric-lab) Phase 2/3 RCT for BPC-157 in any indication
- Direct comparison of TB-500 (Ac-LKKTETQ) vs Ac-LKKTE metabolite in vivo for wound healing
- Optimal cycle length for chronic compression neuropathy specifically (4 vs 6 vs 8 weeks)
- Whether intra-articular vs SC injection produces meaningfully different outcomes (Lee & Padgett used intra-articular)
- Long-term cancer-angiogenesis safety data in human cohorts
- Quantified contribution of TB-500 add-on vs BPC-157 monotherapy in published human data
- Optimal post-cycle washout duration before re-cycling
- Whether full TB-4 (RegeneRx pipeline) outperforms TB-500 heptapeptide if directly compared
References
BPC-157 + TB4 Knee Pain Study (Lee & Padgett, 2021)
only published human study combining the two; n=16, knee pain, 87.5% improvement
View StudyBPC-157 Systematic Review (Vasireddi et al., 2025)
36 articles, orthopedic sports medicine focus, HSS Journal
View StudyThymosin β4 Clinical Wound Healing (Treadwell et al., 2012)
Phase 2 stasis/pressure ulcers, accelerated healing
View StudyThymosin β4 Regenerative Properties Review (Goldstein et al., 2012)
multi-functional regenerative peptide review
View StudyBPC-157 Achilles Tendon Healing (2003)
00110-4) — rat Achilles transection, improved biomechanics
View StudyThymosin β4 Wound Healing Acceleration (1999)
rat full-thickness wounds, 42-61% faster re-epithelialization
View StudyPPInteractions8 compounds▸
| Peptide | Status | Note |
|---|---|---|
Growth Hormone (HGH) | Synergistic | BPC-157 upregulates GH receptors, potentially enhancing tissue repair effects. Combined use may accelerate recovery. |
CJC-1295/Ipamorelin | Synergistic | GH secretagogues complement the Wolverine Stack by increasing endogenous growth hormone, which supports tissue repair processes. |
PEG-MGF | Synergistic | MGF activates satellite cells while BPC-157/TB-500 promote tissue repair through different pathways. May enhance muscle recovery. |
GHK-Cu | Compatible | Copper peptide promotes collagen synthesis and wound healing through different mechanisms. No negative interactions expected. |
NSAIDs | Monitor Combination | BPC-157 has shown protective effects against NSAID-induced GI damage in studies, but long-term combination effects unknown. |
Corticosteroids | Use Caution | Steroids may counteract some healing effects. BPC-157 has shown ability to reverse some corticosteroid-induced damage in animal models. |
Anticoagulants | Monitor Combination | Both peptides promote angiogenesis. Monitor for any bleeding issues when combined with blood thinners. |
Chemotherapy Agents | Avoid Combination | Angiogenesis promotion could theoretically support tumor growth. Contraindicated with any cancer history or treatment. |
PP Community insights — click to load ▸
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.